Bradley Mark J. increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,040 shares of the company’s stock after purchasing an additional 1,435 shares during the period. Eli Lilly and Company accounts for 4.7% of Bradley Mark J.’s portfolio, making the stock its 2nd largest holding. Bradley Mark J.’s holdings in Eli Lilly and Company were worth $6,539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently bought and sold shares of LLY. Norges Bank bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $3,416,206,000. Moneta Group Investment Advisors LLC boosted its holdings in Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after buying an additional 5,440,731 shares during the last quarter. Morgan Stanley grew its position in shares of Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the period. Envestnet Asset Management Inc. raised its position in shares of Eli Lilly and Company by 316.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock valued at $217,569,000 after acquiring an additional 1,850,187 shares during the period. Finally, Mizuho Markets Americas LLC boosted its stake in Eli Lilly and Company by 2,882.6% during the 1st quarter. Mizuho Markets Americas LLC now owns 1,765,702 shares of the company’s stock worth $18,090,000 after acquiring an additional 1,706,502 shares during the last quarter. 81.38% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have commented on LLY. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $630.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 5th. Royal Bank of Canada raised their price objective on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Truist Financial boosted their target price on Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Credit Suisse Group raised their price target on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 9th. Finally, StockNews.com assumed coverage on Eli Lilly and Company in a research report on Thursday, August 17th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $532.78.
Check Out Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
Shares of NYSE LLY opened at $598.88 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. The company has a market cap of $568.51 billion, a PE ratio of 83.29, a price-to-earnings-growth ratio of 2.36 and a beta of 0.32. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.13. The business’s 50 day moving average price is $504.85 and its two-hundred day moving average price is $433.48.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.25 EPS. On average, analysts predict that Eli Lilly and Company will post 9.83 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.
Insider Activity at Eli Lilly and Company
In other news, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 34,156 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the completion of the transaction, the insider now directly owns 101,387,286 shares in the company, valued at $46,037,938,826.88. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,010,309 shares of company stock worth $21,095,701,670. Corporate insiders own 0.13% of the company’s stock.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Articles
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
Leave a Reply